These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16234281)

  • 1. A proposal for financing postmarketing drug safety studies by augmenting FDA user fees.
    Carpenter D
    Health Aff (Millwood); 2005; Suppl Web Exclusives():W5-469-80. PubMed ID: 16234281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. User-fee boost would up safety, reputations. A new paper suggests that drug makers, FDA can't afford not to raise user fees.
    Med Health; 2005 Oct; 59(39):2, 4. PubMed ID: 16279192
    [No Abstract]   [Full Text] [Related]  

  • 3. The FDA and drug safety: a proposal for sweeping changes.
    Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL
    Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Confidentiality laws and secrecy in medical research: improving public access to data on drug safety.
    Kesselheim AS; Mello MM
    Health Aff (Millwood); 2007; 26(2):483-91. PubMed ID: 17339677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large clinical trials in epilepsy: funding by the NIH versus pharmaceutical industry.
    Privitera M
    Epilepsy Res; 2006 Jan; 68(1):52-6. PubMed ID: 16377139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
    Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
    Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA user fees and innovation.
    Somberg J
    Am J Ther; 2008; 15(2):97. PubMed ID: 18356626
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety monitoring of drugs granted exclusivity under the Best Pharmaceuticals for Children Act: what the FDA has learned.
    Mathis LL; Iyasu S
    Clin Pharmacol Ther; 2007 Aug; 82(2):133-4. PubMed ID: 17632537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA user fee plan gets some support from drug makers.
    Weissenstein E
    Mod Healthc; 1992 Aug; 22(33):20. PubMed ID: 10119804
    [No Abstract]   [Full Text] [Related]  

  • 10. Food and Drug Administration surveillance of dermatology-related and nondermatology-related prescription drug advertising in the USA, 2000-2003.
    Cowden AL; Katz KA
    Br J Dermatol; 2006 May; 154(5):950-8. PubMed ID: 16634900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Kennedy version of the Drug Regulation Reform Act.
    Greenberg RB
    Am J Hosp Pharm; 1979 Sep; 36(9):1230-4. PubMed ID: 386790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New law gives FDA more influence to monitor drug safety.
    Wadman M
    Nat Med; 2007 Nov; 13(11):1269. PubMed ID: 17987008
    [No Abstract]   [Full Text] [Related]  

  • 13. New law broadens FDA safety authority, renews user fees.
    Fox JL
    Nat Biotechnol; 2007 Nov; 25(11):1189-90. PubMed ID: 17989653
    [No Abstract]   [Full Text] [Related]  

  • 14. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The new Food and Drug Administration drug package insert: implications for patient safety and clinical care.
    Watson KT; Barash PG
    Anesth Analg; 2009 Jan; 108(1):211-8. PubMed ID: 19095852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk we bear: the effects of review speed and industry user fees on new drug safety.
    Olson MK
    J Health Econ; 2008 Mar; 27(2):175-200. PubMed ID: 18207263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA user fee may speed approval of Alzheimer's, Parkinson's drugs.
    Geriatrics; 1992 Dec; 47(12):15-6. PubMed ID: 1446840
    [No Abstract]   [Full Text] [Related]  

  • 19. Funding pharmaceutical innovation through direct tax credits.
    Lybecker KM; Freeman RA
    Health Econ Policy Law; 2007 Jul; 2(Pt 3):267-84. PubMed ID: 18634650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
    Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.